{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-014547","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.211813+00:00","generated_at":"2026-05-29T23:49:26.064410+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M","bullets":["Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).","Operating expenses fell 52% to $1.5M on $3.1M in annualized cost savings from restructuring.","Cash and cash equivalents were $4.7M as of September 30, 2024.","Accelerated enrollment in global pilot study for TAEUS liver fat assessment; activated site at LMU Germany.","Added AI/ML/DL features to TAEUS; IP portfolio expanded to 82 issued patents."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-014547","json":"https://secwatch.observer/filing/0001654954-24-014547.json","markdown":"https://secwatch.observer/filing/0001654954-24-014547.md","text":"https://secwatch.observer/filing/0001654954-24-014547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424014547/0001654954-24-014547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424014547/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:49:26.064410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}